JP2003505111A5 - - Google Patents

Download PDF

Info

Publication number
JP2003505111A5
JP2003505111A5 JP2001513645A JP2001513645A JP2003505111A5 JP 2003505111 A5 JP2003505111 A5 JP 2003505111A5 JP 2001513645 A JP2001513645 A JP 2001513645A JP 2001513645 A JP2001513645 A JP 2001513645A JP 2003505111 A5 JP2003505111 A5 JP 2003505111A5
Authority
JP
Japan
Prior art keywords
tenascin
nucleic acid
nucleic acids
candidate mixture
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001513645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003505111A (ja
Filing date
Publication date
Priority claimed from US09/364,902 external-priority patent/US6232071B1/en
Application filed filed Critical
Publication of JP2003505111A publication Critical patent/JP2003505111A/ja
Publication of JP2003505111A5 publication Critical patent/JP2003505111A5/ja
Pending legal-status Critical Current

Links

JP2001513645A 1999-07-29 2000-01-28 テネイシンcの核酸リガンド Pending JP2003505111A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/364,902 1999-07-29
US09/364,902 US6232071B1 (en) 1990-06-11 1999-07-29 Tenascin-C nucleic acid ligands
PCT/US2000/002167 WO2001009390A1 (en) 1999-07-29 2000-01-28 Tenascin-c nucleic acid ligands

Publications (2)

Publication Number Publication Date
JP2003505111A JP2003505111A (ja) 2003-02-12
JP2003505111A5 true JP2003505111A5 (cg-RX-API-DMAC7.html) 2007-03-01

Family

ID=23436596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001513645A Pending JP2003505111A (ja) 1999-07-29 2000-01-28 テネイシンcの核酸リガンド

Country Status (29)

Country Link
US (4) US6232071B1 (cg-RX-API-DMAC7.html)
EP (1) EP1198589B9 (cg-RX-API-DMAC7.html)
JP (1) JP2003505111A (cg-RX-API-DMAC7.html)
KR (1) KR100605072B1 (cg-RX-API-DMAC7.html)
CN (2) CN100558411C (cg-RX-API-DMAC7.html)
AT (1) ATE405675T1 (cg-RX-API-DMAC7.html)
AU (1) AU767501C (cg-RX-API-DMAC7.html)
BG (1) BG106361A (cg-RX-API-DMAC7.html)
BR (1) BR0013170A (cg-RX-API-DMAC7.html)
CA (1) CA2380473A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2002365A3 (cg-RX-API-DMAC7.html)
DE (1) DE60039986D1 (cg-RX-API-DMAC7.html)
DK (1) DK1198589T3 (cg-RX-API-DMAC7.html)
EA (1) EA004795B1 (cg-RX-API-DMAC7.html)
EE (1) EE200200051A (cg-RX-API-DMAC7.html)
ES (1) ES2310989T3 (cg-RX-API-DMAC7.html)
HK (1) HK1048499B (cg-RX-API-DMAC7.html)
HR (1) HRP20020186A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0202221A3 (cg-RX-API-DMAC7.html)
IL (2) IL147872A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02000819A (cg-RX-API-DMAC7.html)
NO (1) NO20020424L (cg-RX-API-DMAC7.html)
NZ (2) NZ516907A (cg-RX-API-DMAC7.html)
PL (1) PL201637B1 (cg-RX-API-DMAC7.html)
RS (1) RS50426B (cg-RX-API-DMAC7.html)
SK (1) SK1222002A3 (cg-RX-API-DMAC7.html)
UA (1) UA75578C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001009390A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200200747B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US7005260B1 (en) * 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
PT2070939E (pt) 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
EP1552002A4 (en) * 2002-06-18 2006-02-08 Archemix Corp APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
WO2006093932A2 (en) * 2005-03-01 2006-09-08 Cedars-Sinai Medical Center Use of eotaxin as a diagnostic indicator for atherosclerosis and vascular inflammation
UY29460A1 (es) * 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
BRPI0716554A2 (pt) 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f
EP1897562A1 (en) * 2006-09-08 2008-03-12 Bayer Schering Pharma Aktiengesellschaft Aptamers labelled with Gallium-68
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
ES3045958T3 (en) * 2007-07-17 2025-12-01 Somalogic Operating Co Inc Method for generating aptamers with improved off-rates
EP2036981A1 (en) * 2007-09-12 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Aptamers labeled with 18F
WO2010129666A1 (en) 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
GB201114662D0 (en) 2011-08-24 2011-10-12 Altermune Technologies Llc Chemically programmable immunity
CN102533772B (zh) * 2011-12-12 2013-10-09 中国科学院武汉病毒研究所 一种抗hbv诱饵适体及其筛选方法
EP2791686B1 (en) * 2011-12-12 2017-02-15 Oxford University Innovation Limited Tenascin-c and use thereof in rheumatoid arthritis
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US6610841B1 (en) * 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5683874A (en) * 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5436132A (en) * 1993-02-13 1995-07-25 Amano Pharmaceutical Co., Ltd. Quantitative determination of tenascin as glioma marker
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip

Similar Documents

Publication Publication Date Title
AU767501C (en) Tenascin-C nucleic acid ligands
JP2005503795A (ja) 標的化核酸構築物およびそれに関連する使用
AU1600499A (en) Nucleic acid ligands of tissue target
JP2004511250A (ja) 前立腺特異的膜抗原に対する核酸リガンド
JP2009197024A (ja) 金属複合体及びオリゴヌクレオチドから作られた接合体、該接合体を含む薬剤、放射線診断におけるそれらの使用並びにそれらの製造のための方法
TW200812626A (en) Aptamers labeled with 68GA
JP7671279B2 (ja) Ca-ixアプタマー並びにその診断的および治療的使用
US7005260B1 (en) Tenascin-C nucleic acid ligands
CN118477186A (zh) 一种靶向s2亚基的正电子发射断层显像评价治疗变异新冠病毒感染的方法
JP2004503214A5 (cg-RX-API-DMAC7.html)
CN112920248A (zh) 放射性核素99mTc标记的LncRNA HOTAIR靶向探针、制备方法以及显像剂
JP2003502392A (ja) 血液中の抗凝固性オリゴデオキシヌクレオチドアプタマーの寿命延長